Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.

By Miao-Pei Chen, Fu-Mei Chung, Dao‐Ming Chang, J. Tsai, Han-Fen Huang, Shyi-Jang Shin, Yau-Jiunn Lee. Journal of Clinical Endocrinology and Metabolism, 2006

720 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/6ce5d819ff424fdee86993abf997bd5b33f3109d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

1. A. Moschen

In Epidemiology

1. A. Kaser
2. S. Imai
3. A. Moschen

In Physiology

1. S. Imai
2. A. Kaser
3. A. Moschen
4. D. Sinclair
5. G. Steinberg
6. Bruce E. Kemp
7. L. Guarente

Citations in the corpus

• Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. (2007, background): “, 2005), type 2 diabetes (Chen et al., 2006), and obesity in children (Haider et al.”
• Therapeutic potential of NAD-boosting molecules: the in vivo evidence (2018, neutral): “, and Lee, Y.J. (2011). Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review.”
• Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1 (2007, background): “Notably, Chen and colleagues (10) recently described elevated visfatin plasma levels in patients with type 2 diabetes mellitus.”